Event overview and why it matters
Delta Medical hosted a Delta Club in Vinnytsia convening oncologists, hematologists, surgeons, anesthesiologists, nephrologists, and pediatricians for a focused exchange on optimizing outcomes in complex care.
The agenda centered on nutrition in oncology and surgery, iron deficiency in high-risk settings, and evidence-based biologic therapy in metastatic colorectal cancer.
The format emphasized practical takeaways over ceremony, with case-based discussion, product stations, and hands-on exposure to clinical nutrition.
Clinical focus and program highlights
Sessions prioritized three care gaps common in Ukraine and CIS settings: timely nutritional support in oncology and peri-operative pathways, rapid correction of iron deficiency in acute and chronic conditions, and precise biologic selection in metastatic colorectal cancer.
Dialogue tied published evidence to day-to-day constraints in tertiary hospitals, including infusion capacity, lab turnaround, and reimbursement thresholds.
Faculty illustrated how early screening for malnutrition and iron deficiency reduces complications and LOS, while appropriate first-line biologic choice affects survival and resection rates.
Speakers and institutions
- Oleh Shvets, MD, PhD — President, Association of Dietitians of Ukraine; specialist in clinical nutrition and public health (Kyiv). Topic: practical protocols for nutritional support in oncology and surgical wards.
- Yaroslava Haborets, MD — Clinical Oncologist, Medilux Medical and Diagnostic Center (Vinnytsia); ESMO member. Topic: anti-EGFR therapy selection and trial readouts in metastatic colorectal cancer.
- Oleksandr Petrusha, MD — Head, Hematology Clinic, Main Military Clinical Hospital (Kyiv). Topic: managing iron deficiency and anemia in wounded and high-risk patients; operational lessons for hospital teams.
Delta Medical at the event
Delta Medical hosted product stations for Vectibix, Ferinject, and Priora Nutrition to facilitate case-based consultations with physicians.
- Vectibix® (panitumumab) by Amgen — discussed in the context of RAS-wild-type metastatic colorectal cancer and head-to-head data against bevacizumab in left-sided disease.
- Ferinject® (ferric carboxymaltose) by Vifor — discussed for rapid IV iron repletion in anemia due to chronic disease, peri-operative needs, and in complex inpatient settings.
- Priora Nutrition — sip-feeding and tube-feeding medical nutrition used to support oncology and surgical patients; tasting and product Q&A highlighted formulation differences and use cases.
The team led a short clinical quiz on nutrition protocols and arranged follow-up hospital visits to review screening pathways for malnutrition and iron deficiency.
Medical and Hospital Teams collaborated to map typical inpatient flows, from nutrition screening and iron studies to infusion scheduling and discharge planning.
Educational materials emphasized practical algorithms, sample order sets, and checklists.
Post-event, Delta Medical scheduled departmental briefings with several hospitals and committed to share localized order sets and dosing calculators through field teams.
Market and access insights for UA/CIS/EAEU
- Regulatory and HTA: Ukraine’s move toward formal HTA and evidence-based procurement favors therapies with robust RCT data and clear patient selection rules. Hospitals increasingly request concise protocols and budget impact summaries per indication.
- Reimbursement and tenders: For inpatient iron therapy, institutions seek predictable dosing schemes with minimal infusion chair time. For oncology biologics, centers prioritize clear biomarker-driven pathways to limit waste and align with tender criteria.
- Treatment trends: Early nutrition screening is expanding in surgical and oncology departments, driven by complication reduction targets. In mCRC, left-sided, RAS-wild-type disease continues to shift toward anti-EGFR regimens first line in eligible patients; pathology and molecular turnaround times remain rate-limiting.
- Operational enablers: Hospitals request standardized order sets, pharmacy availability of IV iron medicines, and simple infusion scheduling templates. Delta Medical is preparing localized tools aligned to these requests.
About Delta Medical
Delta Medical (Delta Medical Promotions AG, Zurich) is a Swiss pharmaceutical and medical device marketing and distribution group operating across Ukraine, CIS, and the EAEU. We combine regulatory affairs expertise, market access capabilities, and specialty therapy operations to help partners scale evidence-based solutions. To explore partnership or field support, visit www.deltaswiss.eu.
